FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. Royce M, Osgood C, Mulkey F, Bloomquist E, et al. J Clin Oncol 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.

Read + Share

Amedeo Smart

Independent Medical Education

Royce M, Osgood C, Mulkey F, Bloomquist E, et al. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. J Clin Oncol 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.
PMID: 35084948